论文信息 - Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. - 字舞流文

Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.

To the Editor: The tyrosine kinase inhibitor imatinib mesylate specifically inhibits the BCR-ABL kinase, and has shown promising results in phase 1 and 2 trials in patients with chronic myelogenous...

M. Höglund | B. Simonsson | G. Barbany

[1] E. Kjeldsen,et al. Kinetics of BCR‐ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real‐time polymerase chain reaction , 2001, European journal of haematology.

[2] C. Sawyers. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. , 2001, Seminars in hematology.

[3] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[4] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[5] U. Olsson‐Strömberg,et al. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. , 2000, Clinical chemistry.